Matthew Perrone
WOKV News
Washington, DC, United States
Contact Matthew
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Matthew:
Maker of unproven birth drug Makena to pull from US market
The maker of an unproven drug intended to prevent premature births says it will voluntarily remove the product from the United States → Read More
Maker of unproven birth drug Makena to pull from US market
The maker of an unproven drug intended to prevent premature births says it will voluntarily remove the product from the United States → Read More
FDA’s own reputation could be restraining its misinfo fight
The U.S. Food and Drug Administration is taking aim at a new health hazard: online misinformation → Read More
Panel backs moving opioid antidote Narcan over the counter
U.S. health advisers say the overdose-reversal drug naloxone should be made available over the counter → Read More
FDA panel weighs moving opioid antidote over the counter
U.S. health advisers are weighing whether the overdose-reversal drug naloxone should be made available as an over-the-counter medication → Read More
FDA moves to ease rules for blood donations from gay men
The U.S. plans to make it easier for gay and bisexual men to give blood by easing restrictions on groups that typically face higher risks of HIV → Read More
New lawsuits target state restrictions on abortion pills
Supporters of abortion rights have filed separate lawsuits challenging abortion pill restrictions in North Carolina and West Virginia → Read More
US proposes once-a-year COVID shots for most Americans
U.S. health officials want to make COVID-19 vaccinations more like the annual flu shot → Read More
EXPLAINER: New drug slows Alzheimer's but comes with caveats
A new Alzheimer’s drug is hitting the market with experts voicing a lot of caution → Read More
US approves Alzheimer's drug that modestly slows disease
U.S. health officials have approved a new Alzheimer’s drug that modestly slows the brain-robbing disease → Read More
FDA finalizes rule expanding availability of abortion pills
U.S. health officials have finalized a rule change that broadens availability of abortion pills to many more pharmacies, including large chains and mail-order companies → Read More
Panel warns FDA’s beleaguered tobacco unit lacks direction
A new report criticizes the Food and Drug Administration’s efforts to oversee the tobacco industry, including traditional cigarettes and vaping products → Read More
Speedier drug approvals hit slowdown as FDA faces scrutiny
The Food and Drug Administration is slowing its use of a pathway that expedites the approval of promising drugs → Read More
$3.5M gene therapy for hemophilia gets FDA approval
U.S. health regulators have approved the first gene therapy for hemophilia, a blood-clotting disorder with few treatment options → Read More
Sleep apnea device recall drags on, stoking anger from users
A massive recall of sleep apnea machines is expected to drag into next year → Read More
FDA panel backs removal of unproven pregnancy drug
A panel of federal advisers says a pregnancy drug intended to prevent premature births should be withdrawn because it doesn't work → Read More
FDA pushes to remove pregnancy drug, company pushes back
The maker of a drug intended to reduce premature births is making a last-ditch effort to keep its medication on the market, even as health regulators insist that it doesn’t work → Read More
New survey suggests little progress against U.S. teen vaping
The latest government study on teen vaping suggests there’s been little progress in keeping e-cigarettes out of the hands of kids → Read More
NIH to fund unproven ALS drugs under patient-backed law
The U.S. government will soon spend $25 million to help patients access experimental drugs for the incurable illness known as Lou Gehrig's disease → Read More
US outlines plan for long-term baby formula imports
U.S. regulators have revealed their plan to allow foreign baby formula manufactures to stay on the market long term → Read More